Search - tctmd.com

Displaying 361 - 380 of 682

Sort: Relevancy | Date

News Daily News

Obesity Not Benign: Higher Risk of CVD Seen With Excess Weight

Michael O'Riordan

June 05, 2018

News Conference News EuroPCR 2018

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Michael O'Riordan

May 31, 2018

News Conference News EuroPCR 2018

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

Michael O'Riordan

May 23, 2018

News Conference News EuroPCR 2018

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

Shelley Wood

May 22, 2018

News Daily News

PREDICT-1° CVD Risk Calculator, Based on Present-Day Patients, Beats ACC/AHA ‘Pooled Cohort’ Equations

Michael O'Riordan

May 10, 2018

News Industry News

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

April 09, 2018

News Conference News ACC 2018

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Yael L. Maxwell

March 12, 2018

News Conference News CRT 2018

Wait Continues for a Win With Biodegradable-Polymer DES in Patients at High Bleeding Risk: BIO-RESORT

Michael O'Riordan

March 08, 2018

News Daily News

CABG Bests PCI for 5-Year Survival in Biggest Analysis Yet, With Options for Left Main Disease

Yael L. Maxwell

March 08, 2018

News Daily News

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Michael O'Riordan

January 18, 2018

News Industry News

Positive Five-Year Data Published for MiStent in EuroIntervention

January 12, 2018

News Daily News

Proximity to Physical Activity Facilities May Play Role in Body Fat Levels

Michael O'Riordan

December 13, 2017

News Daily News

Ditching Desflurane Could Help Reduce Carbon Footprint of Surgical Procedures

L.A. McKeown

December 08, 2017

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Daily News

New Heart Failure Cases Rising Among Older Adults, MI Survivors

L.A. McKeown

November 24, 2017

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Conference News AHA 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Michael O'Riordan

November 12, 2017

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Four

Shelley Wood

November 02, 2017

Advertisement

Obesity Not Benign: Higher Risk of CVD Seen With Excess Weight

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

PREDICT-1° CVD Risk Calculator, Based on Present-Day Patients, Beats ACC/AHA ‘Pooled Cohort’ Equations

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Wait Continues for a Win With Biodegradable-Polymer DES in Patients at High Bleeding Risk: BIO-RESORT

CABG Bests PCI for 5-Year Survival in Biggest Analysis Yet, With Options for Left Main Disease

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Positive Five-Year Data Published for MiStent in EuroIntervention

Proximity to Physical Activity Facilities May Play Role in Body Fat Levels

Ditching Desflurane Could Help Reduce Carbon Footprint of Surgical Procedures

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

New Heart Failure Cases Rising Among Older Adults, MI Survivors

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Live From Denver: TCT 2017, Day Four

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content